JOSEPH JANKOVIC to Botulinum Toxins, Type A
This is a "connection" page, showing publications JOSEPH JANKOVIC has written about Botulinum Toxins, Type A.
Connection Strength
14.238
-
Treatment response to onabotulinumtoxinA in cervical dystonia patients with anterocollis and retrocollis. Toxicon. 2024 Sep; 248:108035.
Score: 0.759
-
Botulinum toxin treatment in parkinsonism. J Neurol Sci. 2024 01 15; 456:122810.
Score: 0.725
-
Treatment of cervical dystonia with Botox (onabotulinumtoxinA): Development, insights, and impact. Medicine (Baltimore). 2023 Jul 01; 102(S1):e32403.
Score: 0.705
-
Neutralizing Antibody Formation with OnabotulinumtoxinA (BOTOX?) Treatment from Global Registration Studies across Multiple Indications: A Meta-Analysis. Toxins (Basel). 2023 05 17; 15(5).
Score: 0.699
-
Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-na?ve subjects. Curr Med Res Opin. 2021 10; 37(10):1761-1768.
Score: 0.620
-
Exploring the role of botulinum toxin in critical care. Expert Rev Neurother. 2021 08; 21(8):881-894.
Score: 0.619
-
Botulinum Neurotoxin Injections in Childhood Opisthotonus. Toxins (Basel). 2021 02 12; 13(2).
Score: 0.598
-
Reply to Comment on Re-Visiting Immunogenicity Associated with Botulinum Toxin Treatment. Toxins 2019, 11, 491. Toxins (Basel). 2020 01 23; 12(2).
Score: 0.556
-
Reader response: High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology. 2019 10 22; 93(17):766-767.
Score: 0.546
-
Immunogenicity Associated with Botulinum Toxin Treatment. Toxins (Basel). 2019 08 26; 11(9).
Score: 0.540
-
Botulinum Toxin for the Treatment of Hand Tremor. Toxins (Basel). 2018 07 19; 10(7).
Score: 0.500
-
Onabotulinum toxin-A injections for sleep bruxism: A double-blind, placebo-controlled study. Neurology. 2018 02 13; 90(7):e559-e564.
Score: 0.483
-
Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE). J Neurol Sci. 2015 Feb 15; 349(1-2):84-93.
Score: 0.391
-
Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013 Jun 01; 67:94-114.
Score: 0.343
-
Respiratory disorders associated with dystonia. Mov Disord. 2012 Dec; 27(14):1816-9.
Score: 0.339
-
Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE). BMC Neurol. 2011 Nov 04; 11:140.
Score: 0.314
-
Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. Mov Disord. 2011 Jul; 26(8):1521-8.
Score: 0.303
-
Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Disord. 2009 Feb 15; 24(3):407-13.
Score: 0.260
-
Botulinum toxin injection for congenital muscular torticollis presenting in children and adults. Neurology. 2006 Sep 26; 67(6):1083-5.
Score: 0.221
-
Botulinum toxin treatment of facial myoclonus in suspected Rasmussen encephalitis. Mov Disord. 2006 Sep; 21(9):1500-2.
Score: 0.220
-
Botulinum toxin in dermatology - beyond wrinkles and sweat. J Cosmet Dermatol. 2006 Jun; 5(2):169.
Score: 0.216
-
Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology. 2005 Sep 13; 65(5):765-7.
Score: 0.205
-
Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord. 2005 May; 20(5):592-7.
Score: 0.200
-
Evidence-based review of patient-reported outcomes with botulinum toxin type A. Clin Neuropharmacol. 2004 Sep-Oct; 27(5):234-44.
Score: 0.191
-
Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry. 2004 Jul; 75(7):951-7.
Score: 0.189
-
Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin. 2004 Jul; 20(7):981-90.
Score: 0.189
-
Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled Trial. Neurology. 2024 02 27; 102(4):e208091.
Score: 0.184
-
Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2003 Apr 08; 60(7):1186-8.
Score: 0.174
-
Long-term efficacy and safety of botulinum toxin treatment for cervical dystonia: a critical reappraisal. Expert Opin Drug Saf. 2021 Jun; 20(6):695-705.
Score: 0.153
-
Treating severe bruxism with botulinum toxin. J Am Dent Assoc. 2000 Feb; 131(2):211-6.
Score: 0.139
-
Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology. 1999 Dec 10; 53(9):2102-7.
Score: 0.138
-
Minimal clinically important change in patients with cervical dystonia: Results from the CD PROBE study. J Neurol Sci. 2019 Oct 15; 405:116413.
Score: 0.134
-
Hemifacial spasm: clinical findings and treatment. Muscle Nerve. 1998 Dec; 21(12):1740-7.
Score: 0.128
-
The Regions on the Light Chain of Botulinum Neurotoxin Type A Recognized by T Cells from Toxin-Treated Cervical Dystonia Patients. The Complete Human T-Cell Recognition Map of the Toxin Molecule. Immunol Invest. 2018 Jan; 47(1):18-39.
Score: 0.118
-
Influences of HLA DRB1, DQA1 and DQB1 on T-cell recognition of epitopes and of larger regions of the botulinum neurotoxin molecule. Immunol Lett. 2017 10; 190:257-264.
Score: 0.117
-
Submolecular recognition regions of the HN domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. J Neuroimmunol. 2016 11 15; 300:36-46.
Score: 0.110
-
A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord. 1996 May; 11(3):250-6.
Score: 0.107
-
Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache [RETIRED]: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016 05 10; 86(19):1818-26.
Score: 0.107
-
Submolecular recognition of the C-terminal domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. Immunobiology. 2016 Apr; 221(4):568-76.
Score: 0.104
-
Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders. Drug Des Devel Ther. 2015; 9:1913-26.
Score: 0.100
-
IncobotulinumtoxinA (Xeomin?) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated. J Neurol Sci. 2014 Nov 15; 346(1-2):116-20.
Score: 0.095
-
Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). J Neurol. 2014 Jul; 261(7):1309-19.
Score: 0.093
-
Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(?)) injections in blepharospasm. J Neural Transm (Vienna). 2013 Sep; 120(9):1345-53.
Score: 0.086
-
Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. Toxicon. 2013 Jun 01; 67:141-52.
Score: 0.085
-
Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B. J Neuroimmunol. 2011 Dec 15; 240-241:121-8.
Score: 0.079
-
Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN?, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011 Sep 15; 308(1-2):103-9.
Score: 0.077
-
Human T-cell responses to botulinum neurotoxin: proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients. J Neuroimmunol. 2011 Aug 15; 237(1-2):66-72.
Score: 0.077
-
Flu-like symptoms following botulinum toxin therapy. Toxicon. 2011 Jul; 58(1):1-7.
Score: 0.076
-
Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies. Immunobiology. 2011 Jul; 216(7):782-92.
Score: 0.074
-
Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010 Jun; 16(5):316-23.
Score: 0.070
-
Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm. Eur J Neurol. 2009 Dec; 16 Suppl 2:14-8.
Score: 0.069
-
Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A. Neurology. 2008 Sep 23; 71(13):1040; author reply 1040-1.
Score: 0.063
-
Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008 Jul 30; 23(10):1353-60.
Score: 0.063
-
A peptide-based immunoassay for antibodies against botulinum neurotoxin A. J Mol Recognit. 2007 Jan-Feb; 20(1):15-21.
Score: 0.056
-
Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006 Dec 26; 67(12):2233-5.
Score: 0.056
-
Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol. 2007 Feb; 44(5):1029-41.
Score: 0.054
-
Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005 Jul; 20(7):783-91.
Score: 0.051
-
Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms. Chin Med Sci J. 2005 Mar; 20(1):44-7.
Score: 0.049
-
Premonitory sensory phenomenon in Tourette's syndrome. Mov Disord. 2003 Dec; 18(12):1530-3.
Score: 0.045
-
Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response. Immunol Invest. 2002 Aug-Nov; 31(3-4):247-62.
Score: 0.041
-
Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry. 1999 May; 66(5):612-6.
Score: 0.033
-
Dystonia. Nat Rev Dis Primers. 2018 09 20; 4(1):25.
Score: 0.032
-
Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov Disord. 1998 Jan; 13(1):150-4.
Score: 0.030
-
Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule. Immunobiology. 2012 Jan; 217(1):17-27.
Score: 0.019
-
Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment. Mol Immunol. 2008 Sep; 45(15):3878-88.
Score: 0.016